Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Time Is Ripe For Global Action On Orphan Biosimilars

Executive Summary

European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.

You may also be interested in...



Can Biosimilar Orphans Increase Health System Sustainability In The UK?

Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.

Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs

Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.

Is An End To The Combination Therapy Pricing Problem In Sight In The UK?

Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.

Topics

UsernamePublicRestriction

Register

PS143839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel